MINERALYS THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
MINERALYS THERAPEUTICS, INC. (MLYS) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $46.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-03-12
- MINERALYS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-06-30 was $46.00K.
- MINERALYS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-03-31 was $12.51M, a 217.41% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-03-31 was $3.94M.
- MINERALYS THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $3.94M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|
| 2025-06-30 | $46.00K 10-Q · filed 2025-08-12 | $12.55M derived: sum of 2 quarters · filed 2025-08-12 | |
| 2025-03-31 | $12.51M 10-Q · filed 2025-08-12 | ||
| 2024-12-31 | $3.94M 10-K · filed 2026-03-12 | ||
| 2024-03-31 | $3.94M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |